Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial

Ian Boostrom, Yohan Bala, Jelena Minic Vasic, Jelena Gluvakov, Emmanuel Chanard, Andrew H. Barratt, Kirsty Sands, Edward Portal, Laurence Devigne, Lucy C. Jones, Owen B. Spiller*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)
    313 Downloads (Pure)

    Abstract

    Objectives: To evaluate the accuracy, susceptibility and specificity of MYCOPLASMA IST3, the next generation of the most popular culture-based in vitro diagnostic device designed to detect, identify and test the susceptibility of urogenital mycoplasma infections.

    Methods: MYCOPLASMA IST3 was evaluated against culture- and molecular-based gold standard methodologies to detect, identify, enumerate and determine antimicrobial resistance for Mycoplasma hominis and Ureaplasma species in 516 clinical samples collected across France, Serbia and the UK. Sample types included vulvovaginal/endocervical or urethral swabs (dry swab or eSwab((R))), semen and urine samples, which included blinded analysis following addition of a panel of 80 characterized control strains.

    Results: Overall species identification was excellent for both Ureaplasma spp. (98.4% sensitivity, 99.7% specificity) and M. hominis (95.7% sensitivity, 100% specificity) relative to combined colony morphology on agar and quantitative PCR standards. Non-dilution-based bacterial load estimation by the assay was accurate between 83.7% (M. hominis) and 86.3% (Ureaplasma spp.) of the time (increased to 94.2% and 100%, respectively, if 10-fold variance was allowed) relative to colonies counted on agar. Resistance accuracy for Ureaplasma spp. varied from gold standards for only 11/605 of individual tests (major error rate=1.8%) and for 14/917 individual tests for M. hominis (major error rate=1.5%).

    Conclusions: The redesigned MYCOPLASMA IST3 assay eliminated previous shortcomings by providing independent accurate resistance screening of M. hominis and Ureaplasma species, even in mixed infections, with CLSI-compliant thresholds. Specificity, sensitivity and enumeration estimates correlated closely with the confirmatory methods.

    Original languageEnglish
    Pages (from-to)3175-3182
    Number of pages8
    JournalJournal of Antimicrobial Chemotherapy
    Volume76
    Issue number12
    Early online date3 Sept 2021
    DOIs
    Publication statusPublished - 1 Dec 2021

    Bibliographical note

    Funding Information: A.H.B. was supported by the Knowledge Economy Skills Scholarship 2 (KESS2) programme of funding (grant #80815) for his MPhil under the supervision of O.B.S. and L.C.J. Partial funding support for this project was
    provided by bioMérieux to O.B.S. and I.B.

    Open Access: This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

    Publisher Copyright: © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

    Citation: Ian Boostrom, Yohan Bala, Jelena Minic Vasic, Jelena Gluvakov, Emmanuel Chanard, Andrew H Barratt, Kirsty Sands, Edward Portal, Laurence Devigne, Lucy C Jones, Owen B Spiller, Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial, Journal of Antimicrobial Chemotherapy, Volume 76, Issue 12, December 2021, Pages 3175–3182,

    DOI: https://doi.org/10.1093/jac/dkab320

    Fingerprint

    Dive into the research topics of 'Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial'. Together they form a unique fingerprint.

    Cite this